PL3768263T3 - Podawanie kompozycji farmaceutycznej w sposób ciągły dla leczenia zaburzeń neurodegeneracyjnych - Google Patents
Podawanie kompozycji farmaceutycznej w sposób ciągły dla leczenia zaburzeń neurodegeneracyjnychInfo
- Publication number
- PL3768263T3 PL3768263T3 PL19715590.6T PL19715590T PL3768263T3 PL 3768263 T3 PL3768263 T3 PL 3768263T3 PL 19715590 T PL19715590 T PL 19715590T PL 3768263 T3 PL3768263 T3 PL 3768263T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- pharmaceutical composition
- neurodegenerative disorders
- continuous administration
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1850327 | 2018-03-23 | ||
| PCT/SE2019/050260 WO2019182506A1 (en) | 2018-03-23 | 2019-03-22 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3768263T3 true PL3768263T3 (pl) | 2026-01-26 |
Family
ID=66041617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19715590.6T PL3768263T3 (pl) | 2018-03-23 | 2019-03-22 | Podawanie kompozycji farmaceutycznej w sposób ciągły dla leczenia zaburzeń neurodegeneracyjnych |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11547689B2 (https=) |
| EP (1) | EP3768263B1 (https=) |
| JP (1) | JP7485874B2 (https=) |
| KR (2) | KR20200136008A (https=) |
| CN (2) | CN118121710A (https=) |
| AU (1) | AU2019237857B2 (https=) |
| ES (1) | ES3053690T3 (https=) |
| HR (1) | HRP20251502T1 (https=) |
| IL (1) | IL277553B2 (https=) |
| MY (1) | MY199846A (https=) |
| NZ (1) | NZ768098A (https=) |
| PH (1) | PH12020551527A1 (https=) |
| PL (1) | PL3768263T3 (https=) |
| RS (1) | RS67469B1 (https=) |
| SG (1) | SG11202009215PA (https=) |
| WO (1) | WO2019182506A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113197851A (zh) | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| EP3768263B1 (en) | 2018-03-23 | 2025-10-29 | LobSor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US20080118556A1 (en) * | 1998-11-02 | 2008-05-22 | Elan Corporation, Plc | Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| DE602004031134D1 (de) | 2003-08-29 | 2011-03-03 | Transform Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
| EP1796687A2 (en) * | 2004-09-14 | 2007-06-20 | Elixir Pharmaceuticals, Inc. | Combination therapy for controlled carbohydrate digestion |
| CN101132777A (zh) * | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| WO2007138086A1 (en) | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals Gmbh | Long term 24 hour intestinal administration of levodopa/carbidopa |
| US8741342B2 (en) * | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| EP2252284B1 (en) | 2008-02-06 | 2011-05-25 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| CN102202656A (zh) * | 2008-08-15 | 2011-09-28 | 蒂宝制药公司 | 治疗和预防cns障碍的胃滞留药用组合物 |
| EA026419B1 (ru) | 2010-03-04 | 2017-04-28 | Орион Корпорейшн | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона |
| PT2640358T (pt) | 2010-11-15 | 2018-02-23 | Neuroderm Ltd | Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| JP6622310B2 (ja) * | 2014-09-04 | 2019-12-18 | ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 |
| US10555922B2 (en) * | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| EP3768263B1 (en) * | 2018-03-23 | 2025-10-29 | LobSor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
-
2019
- 2019-03-22 EP EP19715590.6A patent/EP3768263B1/en active Active
- 2019-03-22 KR KR1020207030580A patent/KR20200136008A/ko not_active Ceased
- 2019-03-22 CN CN202410175227.3A patent/CN118121710A/zh active Pending
- 2019-03-22 JP JP2020551353A patent/JP7485874B2/ja active Active
- 2019-03-22 US US17/040,511 patent/US11547689B2/en active Active
- 2019-03-22 RS RS20251225A patent/RS67469B1/sr unknown
- 2019-03-22 MY MYPI2020004885A patent/MY199846A/en unknown
- 2019-03-22 KR KR1020257008573A patent/KR20250043584A/ko active Pending
- 2019-03-22 HR HRP20251502TT patent/HRP20251502T1/hr unknown
- 2019-03-22 ES ES19715590T patent/ES3053690T3/es active Active
- 2019-03-22 IL IL277553A patent/IL277553B2/en unknown
- 2019-03-22 SG SG11202009215PA patent/SG11202009215PA/en unknown
- 2019-03-22 PL PL19715590.6T patent/PL3768263T3/pl unknown
- 2019-03-22 AU AU2019237857A patent/AU2019237857B2/en active Active
- 2019-03-22 CN CN201980034384.XA patent/CN112261940B/zh active Active
- 2019-03-22 WO PCT/SE2019/050260 patent/WO2019182506A1/en not_active Ceased
- 2019-03-22 NZ NZ768098A patent/NZ768098A/en unknown
-
2020
- 2020-09-22 PH PH12020551527A patent/PH12020551527A1/en unknown
-
2022
- 2022-11-04 US US17/981,092 patent/US12251368B2/en active Active
-
2025
- 2025-02-12 US US19/051,884 patent/US20250213518A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL277553A (en) | 2020-11-30 |
| CN112261940B (zh) | 2024-02-27 |
| US12251368B2 (en) | 2025-03-18 |
| HRP20251502T1 (hr) | 2026-02-13 |
| KR20200136008A (ko) | 2020-12-04 |
| NZ768098A (en) | 2025-12-19 |
| JP2021519272A (ja) | 2021-08-10 |
| AU2019237857B2 (en) | 2024-11-21 |
| EP3768263A1 (en) | 2021-01-27 |
| US20230157989A1 (en) | 2023-05-25 |
| EP3768263B1 (en) | 2025-10-29 |
| ES3053690T3 (en) | 2026-01-23 |
| US20250213518A1 (en) | 2025-07-03 |
| US20210015782A1 (en) | 2021-01-21 |
| AU2019237857A1 (en) | 2020-10-08 |
| US11547689B2 (en) | 2023-01-10 |
| IL277553B2 (en) | 2024-11-01 |
| CN112261940A (zh) | 2021-01-22 |
| JP7485874B2 (ja) | 2024-05-17 |
| SG11202009215PA (en) | 2020-10-29 |
| CN118121710A (zh) | 2024-06-04 |
| EP3768263C0 (en) | 2025-10-29 |
| KR20250043584A (ko) | 2025-03-28 |
| MY199846A (en) | 2023-11-24 |
| PH12020551527A1 (en) | 2021-07-19 |
| WO2019182506A1 (en) | 2019-09-26 |
| IL277553B1 (en) | 2024-07-01 |
| RS67469B1 (sr) | 2025-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| SG11202106160WA (en) | Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient | |
| ZA202002166B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL286677A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| GB201610056D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis | |
| IL286688A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| GB201911868D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| GB201610055D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis | |
| IL269400A (en) | Medicines and preparations for the treatment of eye disorders | |
| IL286685A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| IL277553A (en) | Preparations for the treatment of neurodegenerative diseases by continuous administration | |
| IL257336B (en) | Pharmaceutical compounds and preparations for the prevention or treatment of parasitic diseases | |
| EP3338771A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF TRAMADOL-ETORICOXIB CHLORHYDRATE FOR THE TREATMENT OF PAIN | |
| GB201702603D0 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| HUE069327T2 (hu) | Neurodegeneratív betegségek megelõzésére vagy kezelésére szolgáló gyógyszer | |
| PL3743043T3 (pl) | Kompozycje farmaceutyczne do leczenia bólu pooperacyjnego | |
| HUE065421T2 (hu) | Nazális adagolású rifampicint tartalmazó gyógyszerészeti készítmény demencia kezelésére | |
| GB201902490D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| HK40045197A (zh) | 用於治疗神经退行性疾病的药物组合物的连续施用 | |
| HUE053866T2 (hu) | Gyógyászati készítmény székrekedés kezelésére | |
| GB201807222D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammation disorders | |
| HK40052948A (en) | Pharmaceutical compounds for the treatment of complement factor d medical disorders | |
| GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies |